Reports of Practical Oncology and Radiotherapy最新文献

{"title":"Spinal relapse of Erdheim-Chester disease detected on ¹⁸F-FDG PET/CT.","authors":"Yassir Benameur, Omar Ait Sahel, Jaafar El Bakkali, Salah Nabih Oueriagli, Ikram Zahfir, Meryem Aboussabr, Abderrahim Doudouh","doi":"10.5603/rpor.109098","DOIUrl":"10.5603/rpor.109098","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"307-309"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commissioning in water of HDR Valencia skin applicators.","authors":"Luis Ángel Quiñones Rodríguez, Lydia Pérez Ríos, María Amparo Iborra Oquendo","doi":"10.5603/rpor.109847","DOIUrl":"10.5603/rpor.109847","url":null,"abstract":"<p><strong>Background: </strong>In surface brachytherapy, Valencia applicators are widely used for treating non-melanoma skin cancers. Typically, plastic phantoms are used for dosimetric measurements since the setup is simpler, unlike external beam radiation therapy, where water is the standard medium for dosimetry.</p><p><strong>Materials and methods: </strong>This study focuses on the commissioning in water of Valencia applicators using iridium-192 (Ir¹⁹²) Flexisource and Elekta Flexitron high-dose-rate brachytherapy (HDR-BT). Measurements of percentage depth dose and dose rate per unit kerma strength were performed with various detectors, including PTW microDiamond, microSilicon X, and Diode E for percentage depth dose (PDD) measurements. Roos, Semiflex 3D, and PinPoint 3D ionization chambers were used for dose rates dosimetry.By means of 3D printing, custom adapters were developed to integrate Valencia applicators with water phantom MP1, enabling precise dosimetric measurements in water.</p><p><strong>Results: </strong>Results showed that all detectors were suitable for in water PDD measurements, with minor differences attributed to setup geometry. Dose rates measured with the Semiflex 3D and Pinpoint 3D chambers revealed minimal discrepancies, while the Roos chamber exhibited a notable volume effect, producing measurements approximately 10% lower than expected. The study also shows that the source positioning within the applicator significantly influenced dose profiles, whereas PDD measurements' main influence is inverse square law, being more tolerant to positioning errors.</p><p><strong>Conclusions: </strong>Overall, it is feasible to adapt external beam radiation therapy (EBRT) dosimetry equipment as ionization chambers and water phantoms for use in surface brachytherapy commissioning. Custom 3D-printed adapters facilitate this integration, allowing in water measurements, thus reducing uncertainties in clinical dose calculations.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"214-219"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic radiation-induced dermatitis: what is new in 2024? A narrative review.","authors":"Eryk Siedlecki, Piotr Remiszewski, Mateusz J Spałek","doi":"10.5603/rpor.110468","DOIUrl":"10.5603/rpor.110468","url":null,"abstract":"<p><p>Radiation exposure can cause two main types of dermatitis: acute radiation dermatitis (ARD) and chronic radiation dermatitis (CRD). ARD appears days to weeks after exposure, with symptoms including redness, peeling, and blistering. At the same time, CRD develops over months to years, resulting in long-lasting skin changes such as fibrosis, pigmentation, and telangiectasia. Most studies on radiation dermatitis focus on ARD, yet doctors must update their knowledge about CRD, as it affects approximately one-third of patients. This review aims to present the current knowledge of CRD as an update to our previous work published in 2016. We focused mainly on the latest advancements and challenges in its prevention, diagnosis, and treatment as of 2024. It is even more critical to treat CRD effectively, as during the last eight years, the life expectancy of oncologic patients has significantly improved. Recent studies unraveled much about the pathophysiological mechanisms behind CRD, including the roles of micro ribonucleoacids (miRNAs), epigenetic factors, and epithelial-mesenchymal transition. Innovations in radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT) and personalized protective shields, have reduced the incidence and severity of CRD. New pharmacological interventions, including topical agents and systemic medications, can manage symptoms like erythema, dryness, and fibrosis. However, there are still substantial challenges in managing the long-term effects of CRD. Combining genetic and imaging data may be a way to predict who is likely to develop CRD and to create personalized treatment plans.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"289-303"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated treatment planning for brain and spinal metastases.","authors":"Giulianne Rivelli Rodrigues Zaratim, Ricardo Gomes Dos Reis, Luis Felipe Oliveira E Silva","doi":"10.5603/rpor.110096","DOIUrl":"10.5603/rpor.110096","url":null,"abstract":"<p><strong>Background: </strong>Automation improves workflow efficiency in treatment planning, especially for urgent spinal and cerebral cases. This study develops an automated planning approach for brain and spinal metastases using the Eclipse Scripting API.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 82 patients with spinal metastases and 93 with brain metastases. For spinal metastases, three beam arrangements were tested. For whole-brain radiation therapy (WBRT), the algorithm optimized gantry angles by identifying the largest intersection of the eyes' projections in the beam's eye view (BEV), within specified angular intervals. To reduce radiation exposure to the lenses, the algorithm automatically set the fluence to zero within the BEV lens contours, applying a 3 mm margin. Dosimetric analysis assessed dose constraints, and the time required for plan generation was recorded.</p><p><strong>Results: </strong>The median planning target volume (PTV) V99 parameter for WBRT was 97.6%, while for spinal vertebrae irradiation, it ranged from 95.9% to 98.8%. Regarding the clinical target volume (CTV), the median V99 parameter for WBRT was 99.1%, and for spinal vertebrae, it was 100%. The maximum point doses for these sites were recorded at 106.2% and 106.3%, respectively. WBRT plan generation required an average of 8 minutes ± 2 minutes and 10 seconds, whereas for spinal vertebrae irradiation, it ranged from 5 minutes and 45 seconds ± 1 minute and 43 seconds to 6 minutes and 10 seconds ± 1 minute and 45 seconds.</p><p><strong>Conclusions: </strong>This study demonstrates that the developed algorithms for treatment planning can efficiently generate high-quality treatment plans for both sites within a short timeframe.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"220-226"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the optimal timing for projected dose evaluation in head and neck cancer patients treated with helical tomotherapy.","authors":"Suwapim Chanlaor, Jayanton Patumanond, Chawalit Lakdee, Boriphat Kadman","doi":"10.5603/rpor.110812","DOIUrl":"10.5603/rpor.110812","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to determine the optimal time point at which the projected dose most accurately corresponds to the accumulated dose in head and neck cancer patients treated with helical tomotherapy. Dose metric differences between the International Commission on Radiation Units and Measurements Report 83 (ICRU83) (D50%) and Radiation Therapy Oncology Group (RTOG) (D95%) protocols were also evaluated for the planning target volume and critical organs, including the parotid glands, spinal cord, and brainstem.</p><p><strong>Materials and methods: </strong>This methods-oriented study analyzed data from 61 head and neck cancer patients treated with helical tomotherapy. It compared projected and accumulated doses across the treatment course, assessing dose discrepancies at fractions 1, 5, 10, 15, 20, 25, and 30. A ±3% threshold was defined as the acceptable deviation for both target volumes and critical organs.</p><p><strong>Results: </strong>Among the 61 patients analyzed, 70.5% had T3-T4 tumors and 68.8% were planned using the ICRU83 protocol. No deviations exceeding ±3% were observed in planning target volume dose 70 Gy (PTV70) (D50%) under ICRU83 protocol, whereas 35.0% of RTOG protocol (D95%) cases showed dose underestimation during fractions 1, 5, and 10. Deviations exceeding ±3% occurred most frequently in the left parotid gland (up to 75.4% of cases), followed by the right parotid gland, spinal cord and brainstem, particularly during early fractions.</p><p><strong>Conclusions: </strong>Projected dose proved to be a reliable metric for evaluating dose consistency, with D50% under ICRU83 protocol stable from early treatment and D95% under RTOG protocol consistent after fraction 15. However, variations in projected doses for organs at risk emphasize the need for cautious interpretation and individualized adaptive planning.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"186-193"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of radiotherapy in stabilization of oligoprogressive lesions of malignant melanoma treated with immunotherapy.","authors":"Martin Palkovsky, Alzbeta Hlodakova, Jindrich Kopecky, Marek Pasek, Jiri Svec, Monika Arenbergerova, Petr Arenberger, Renata Soumarova","doi":"10.5603/rpor.110095","DOIUrl":"10.5603/rpor.110095","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate the effectiveness of radiotherapy (RT) in stabilizing oligoprogressive disease (OPD) in melanoma patients undergoing immunotherapy. We hypothesize that RT's efficacy in disease stabilization is influenced by factors such as dose, fractionation, metastatic burden, and the timing of OPD onset relative to immunotherapy initiation.</p><p><strong>Materials and methods: </strong>A retrospective observational study was conducted at two Czech university hospitals. Inclusion criteria encompassed metastatic melanoma patients undergoing immunotherapy with checkpoint inhibitors who developed OPD between January 2018 and May 2023. Exclusion criteria included central nervous system (CNS) involvement, discontinuation of systemic therapy during or after RT, and treatments other than immune checkpoint inhibitors. Patients were stratified based on RT initiation timing (< 6 months or > 6 months from immunotherapy start) to assess primary and acquired resistance. 34 patients were included, with RT administered for extracranial OPD. Among these, local control was achieved in 21 patients.</p><p><strong>Results: </strong>Higher doses of RT [> 40 Gy the equivalent dose in 2 Gy fractions (EQD2)] correlated with improved local control. Patients with fewer than five irradiated lesions experienced better progression-free survival (PFS) and overall survival (OS), however, the difference did not reach statistical significance. Multivariate analysis revealed that patients who received RT after > 6 months since initiation of immune checkpoint inhibitor (ICI) had significantly longer PFS. This study suggests, that RT is a viable option for stabilizing OPD in melanoma patients treated with immunotherapy, especially when administered later in the treatment course.</p><p><strong>Conclusions: </strong>Improved OS and PFS outcomes suggest that delayed OPD may indicate acquired resistance, which benefits from RT. Future studies should refine RT parameters and patient selection criteria to optimize clinical outcomes.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"227-238"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147933693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interobserver variability in dominant intraprostatic lesion delineation using ⁶⁸Ga-PSMA PET/CT for localized prostate cancer.","authors":"Bennur Zeynan Devran, Ilknur Alsan Cetin, Feyza Cagliyan, Salih Özgüven, Tunç Öneş","doi":"10.5603/rpor.110469","DOIUrl":"10.5603/rpor.110469","url":null,"abstract":"<p><strong>Background: </strong>We evaluated interobserver variability in delineating the dominant intraprostatic lesion (DIL) using Gallium-68 labeled prostate-specific membrane antigen ligand (⁶⁸Ga-PSMA) positron emission tomography/computed tomography (PET/CT) and analyzed how patient and tumor characteristics impact this variability.</p><p><strong>Materials and methods: </strong>Twenty patients diagnosed with localized prostate cancer who underwent definitive radiotherapy were retrospectively analyzed. Three nuclear medicine specialists and one radiation oncologist independently delineated DIL volumes. Intraclass correlation coefficients (ICC) were used to assess interobserver agreement. The effects of clinical and tumor characteristics, including prostate volume, DIL size, maximum standardized uptake value (SUV_max) values, and extraprostatic extension, were also analyzed.</p><p><strong>Results: </strong>The interobserver agreement among all four experts was almost perfect [intraclass correlation coefficient (ICC) = 0.83; 95% confidence interval (CI): 0.68-0.92]. The nuclear medicine specialist with access to multiparametric magnetic resonance imaging (mpMRI) data delineated significantly smaller DIL volumes compared to nuclear medicine specialists without mpMRI access (p < 0.001). The radiation oncologist also delineated smaller and more conservative DIL volumes than all nuclear medicine specialists (p = 0.002). Agreement decreased (ICC < 0.8) in patients with a prostate volume > 40 cc, DIL length > 15 mm, SUV_max > 10, or evidence of seminal vesicle invasion or extracapsular extension. PSA and SUVmax values significantly correlated with patients' DIL volumes (p < 0.05).</p><p><strong>Conclusions: </strong>Although interobserver agreement in DIL delineation was almost perfect, specific patient- and tumor-related factors were associated with increased variability. Particular caution is warranted when outlining DILs in patients with larger prostate volumes, greater lesion lengths, higher SUV_max values, or extraprostatic extension. These findings highlight the need for consensus-based contouring guidelines to improve standardization and consistency in prostate cancer treatment planning.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"259-268"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A forgotten option: megestrol acetate's effectiveness and safety in HR+/HER2-negative metastatic breast cancer - insights from a contemporary patient cohort.","authors":"Marek Ziobro, Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Marcin Kubeczko, Miroslawa Puskulluoglu","doi":"10.5603/rpor.110809","DOIUrl":"10.5603/rpor.110809","url":null,"abstract":"<p><strong>Background: </strong>The ABC 6/7 guidelines recommend megestrol acetate (MA) as a later-line hormonal option for HR+/HER2- metastatic breast cancer (MBC) when targeted therapies are unavailable, though current evidence on its efficacy and safety remains limited.</p><p><strong>Materials and methods: </strong>This retrospective study assessed the effectiveness and tolerability of MA (200-400 mg) in HR+/HER2- MBC patients treated at the reference Cancer Center in Poland (January 2020-December 2024). Patients on other systemic therapies or with active malignancies were excluded. Median progression-free survival (mPFS) and overall survival (mOS) were assessed using Kaplan-Meier estimates and Cox proportional hazards models. Statistical significance was defined as p < 0.05.</p><p><strong>Results: </strong>The study included 20 patients (median age: 70.2 years; range: 49.5-92.4) with a median follow-up of 4.5 months [interquartile range (IQR): 0.34-9.99]. Patients had received a median of 2.5 prior systemic therapies (IQR: 1-5) and 2 prior hormonal therapy lines (IQR: 0-4). Eleven patients (55.0%) had exhausted hormonal options, and eleven (55.0%) were ineligible for chemotherapy, including eight (40.0%) with no other systemic treatment options. mPFS was 2.6 months [95% confidence interval (CI): 1.37-4.32], and mOS, 4.1 months (95% CI: 1.5-10.8). Performance status 2-4 was associated with higher risk of progression or death [hazard ratio (HR) = 2.75] and death (HR = 9.42) <i>vs</i>. PS 1. One grade 2 thromboembolic event occurred.</p><p><strong>Conclusions: </strong>Despite the small sample size, the observed outcomes support the continued inclusion of MA in ABC guidelines for the treatment of HR+/HER2- MBC, further substantiated by the comprehensive review of clinical evidence and recommendations presented in this article.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"269-278"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited pelvic radiotherapy in post-operative uterine carcinoma.","authors":"Hadrian Noel Alexander, Avinash H Udayashankara, Silpa Johnson, Nirmala Srikantia, John M Raj","doi":"10.5603/rpor.109096","DOIUrl":"10.5603/rpor.109096","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant external beam radiotherapy (EBRT) is a standard of care for all patients with intermediate and high-risk uterine carcinomas. In EBRT, target volume includes tumour bed along with pelvic lymph nodes. However, benefit of nodal irradiation in patients with negative nodes after an adequate pelvic lymph node dissection is unclear. This retrospective study aims to analyse outcome of limited pelvic radiotherapy (LPRT) in postoperative carcinoma of cervix and endometrium.</p><p><strong>Materials and methods: </strong>All postoperative carcinoma of cervix and endometrium cases treated with adjuvant LPRT from January 2013 to December 2023 were included in the analysis. Patients were treated to a dose of 5040 cGy using 3-dimensional conformal radiotherapy. In patients with cervical stroma involvement, along with an EBRT dose of 4500 cGy, high dose rate (HDR) brachytherapy was also delivered. We plan analysed patterns of failure, overall survival (OS), recurrence-free survival (RFS), and treatment-associated toxicities.</p><p><strong>Results: </strong>Out of 391 screened postoperative carcinoma cervix and endometrium patients, 37 received LPRT. With a median follow-up of 51.1 months, 2 patients were lost to follow-up. The 5-year RFS and OS were 75.5% and 73.2%, respectively. Among 4 patients who developed recurrence during the 5-year analysis period, all had distant recurrences. Grade ≥ 2 gastrointestinal and genitourinary toxicities were observed in 29.7% of patients in acute phase and 2.7% as late effects. Lymphedema occurred in 8.1%, with no Grade 4 or 5 toxicities reported.</p><p><strong>Conclusions: </strong>LPRT without lymph node irradiation results in good local control in the selected group of post operative uterine carcinomas.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"159-166"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Video-based postural alignment improves accuracy of breath hold treatment delivery in breast cancer patients.","authors":"Rita Alaimo, Edy Ippolito, Guenda Meffe, Marta Moraschi, Rita Falconi, Sonia Silipigni, Gian Marco Petrianni, Carlo Greco, Michele Fiore, Sara Ramella","doi":"10.5603/rpor.110471","DOIUrl":"10.5603/rpor.110471","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant radiotherapy can be considered the standard of care for patients diagnosed with primary breast cancer who have undergone breast-conserving surgery. Left breast cancer receiving adjuvant deep inspiration breath hold (DIBH) were evaluated. A technique for monitoring patient position during DIBH is the surface guided radiation therapy (SGRT) as Vision AlignRT. The aim of this study was to estimate setup accuracy with AlignRT compared to AlignRT Advance in a cohort of patients undergoing DIBH treatment of breast cancer.</p><p><strong>Materials and methods: </strong>One hundred and fifty-four patients were studied. Patient positioning was informed using SGRT and verified by cone beam computed tomography (CBCT). Patients were divided into groups (G) based on treatment volume and version of Vision AlignRT. Comparison was performed by two tailed t-test. Data were deemed as statistically significant if p < 0.001.</p><p><strong>Results: </strong>The setup error for all patients treated with DIBH radiotherapy (RT) was calculated by CBCT. For left breast treatments, the interfractional displacement in the longitudinal and vertical directions was significantly (p < 0.001) reduced in patients positioned with the advanced version. For breast and supraclavicular lymph node chain and/or internal mammary chain treatments, interfractional displacement in the lateral and vertical directions was significantly (p < 0.001) reduced when the advanced version was used, while for longitudinal displacement the reduction was not significant.</p><p><strong>Conclusions: </strong>Positioning with AlignRT Advance is more accurate for either left breast only or left breast and supraclavicular lymph node chain and/or internal mammary chain treatments.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"250-258"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}